Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.
shimon slavin, MD
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Israel: Israeli Health Ministry Pharmaceutical Administration